Journal of obstetrics and gynaecology research · 2019 · 21 citations · 11 references
MedicinePharmacologyPharmacotherapyMenstrual DisordersReproductive EndocrinologyWomen's Health PharmacotherapyAdenomyosisMenopause Hormone TherapyMenopause PharmacotherapyMenstrual CycleReproductive Endocrinology PharmacotherapySide EffectsAbdominal DiscomfortAdverse Symptom ManagementClinical Presentation Of AdenomyosisMedical Records ReviewMenstrual CrampsProgestin Pharmacology
AIM: To evaluate various adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas (n = 90), adenomyosis (n = 3) or both (n = 7). METHODS: One hundred premenopausal women who received ulipristal acetate for 4-12 weeks during 2016 to 2017 were selected. The medical records were reviewed and the following information was collected; adverse symptoms during medication, presence of menorrhagia or menstrual cramps, blood hemoglobin and liver function test. Adverse symptoms were recorded in the medical records as a checklist form including 76 specific progestin-related symptoms. RESULTS: Overall, the most frequent adverse symptom was amenorrhea (43%), followed by weight gain (29%), fatigue (27%), abdominal discomfort (21%), decreased menstrual flow (19%) and dizziness (18%). In 89 symptomatic women (with heavy menstrual bleeding and/or menstrual cramping pain and/or anemia), the most frequent adverse symptom was weight gain (27%) and fatigue (27%), followed by abdominal discomfort (21%), dry eye (18%), facial flushing (17%), dizziness (17%), headache (17%) and increased vaginal discharge (15%). Fourteen women stopped the medication due to unwanted adverse symptoms. Of this discontinuation group, major complaint was fatigue (50%), followed by weight gain (36%) and breast discomfort (35.7%). CONCLUSION: Adverse symptoms were common and discontinuation rate was somewhat higher during short-term course of ulipristal acetate. Information about incidence of various adverse symptoms should be given to women who willing to take ulipristal acetate.
11
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Jacques Donnez, Philippe Bouchard, Lucian Pușcașiu et al. · New England Journal of Medicine · 2012 · 677 citations · Full text
Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Jacques Donnez, Janusz Tomaszewski, Philippe Bouchard et al. · New England Journal of Medicine · 2012 · 607 citations · Full text
Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma
Hiroshi Ishikawa, K Ishi, Vanida A. Serna et al. · Endocrinology · 2010 · 363 citations · Full text
Medicine, Endocrinology, Oncology +12
The spectrum of endometrial pathology induced by progesterone receptor modulators
George L. Mutter, Christine Bergeron, Liane Deligdisch et al. · Modern Pathology · 2008 · 233 citations · Full text
Medicine, Endocrinology, Gynecology +14
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids
Jacques Donnez, Robert Hudeček, Olivier Donnez et al. · Fertility and Sterility · 2014 · 218 citations · Full text